Papers Archive

晨会

共 36 条 · 每页 10 条 · 第 2 / 4 页

11

Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade

Julian Blagg, Philippe Riou, Alexia Hervieu, Eleonora Piumatti, Maria T. Rodriguez-Plata, Paolo Battuello, Adam Peall, Vito Amodio, Pietro Paolo Vitiello, Daniel J.H. Nightingale, Ruzica Bago, Paige Tongue, Tessa Slater, Kalpesh Parmar, Pradip Patel, Javier Rodríguez González, David E. Clark, Gareth W. Langley, Charles Nichols, Alba Guarné, Paul C.M. Winship, Matthew Baker, Martin Drysdale, Giovanni Germano, Alberto Bardelli

共价PMS2抑制剂NP1867使长期体外培养的鼠源肿瘤细胞积累MMR缺陷相关改变，植入小鼠后对抗PD-1更敏感。

 12

Aspirin after curative-intent treatment of colorectal cancer liver metastases (ASAC): a multicentre, phase 3, randomised, double-blind, placebo-controlled trial

Sheraz Yaqub, Morten Valberg, Bjørn Atle Bjørnbeth, Jon-Helge Angelsen, Kristoffer Watten Brudvik, Ina Andrassy Eilertsen, Richard Fristedt, Claus Wilki Fristrup, Stefan Gilg, Oskar Hemmingsson, Bengt Isaksson, Ingebjørg Soterud Juel, Anders Riegels Knudsen, Peter Nørgaard Larsen, Kim Erlend Mortensen, Inge Christoffer Olsen, Per Sandström, Oddvar Mathias Sandvik, Ernesto Sparrelid, Helena Taflin, Ragnhild A Lothe, Kjetil Taskén, ASAC Study Group

ASACⅢ期试验中，肝转移根治性治疗后使用160 mg阿司匹林未改善DFS，并观察到OS与安全性的不利结果。

 13

Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial

Timothy A. Yap, Elisa Fontana, Natalie Cook, Marwan Fakih, Oliver Bechter, Erica S. Tsang, Emiliano Calvo, Kristoffer S. Rohrberg, Javier Ros, Ignacio Matos, John H. Strickler, Malaka Ameratunga, Meredith Pelster, Adam Sharp, Jaspreet Grewal, Susanna Ulahannan, Rajesh Belani, Matthew P. Patricelli, Sophia M. Blake, David Dejardin, Stephen Fowler, Christina Godfried Sie, Astrid Heller, Nina Henkel, Michael Hettich, Angelika Lahr, David Lamparter, Charlotte Lane, Ting Liu, Hélène Meistermann, Christophe Meille, Neil Parrott, Sotirios K. Sotiriou, Denise Reeves, Barbara Romagnoli, Piergiorgio Pettazzoni, Daniel Waterkamp, Matthias Wittwer, Yali Fu, Sophie Postel-Vinay

首次人体Ⅰ期试验中，WRN抑制剂在多线治疗后的MSI实体瘤中显示以疾病稳定为主的活性。

 14

A serpin–myeloid axis in pancreatic cancer heterogeneity and immune evasion

Chiara Falcomatà, Maximilian M. Schaefer, Bhavya Singh, Divya Chhamalwan, Alexander Tepper, Sebastian R. Nielsen, Hunter T. Potak, Maxime Dhainaut, Gurkan Mollaoglu, Matthew D. Park, Miriam Merad, Alessia Baccarini, Brian D. Brown

空间功能筛选显示，胰腺癌中少数serpin阳性细胞可建立富含巨噬细胞的局部生态位，影响邻近细胞的免疫逃逸。

 15

Ceramide synthesis mediates colorectal cancer metastasis through a YAP-driven regenerative program

Swagata Goswami, Qiming Zhang, Abdullah Burak Yildiz, Upasana Das Adhikari, Akhouri Kishore Raghawan, Manon Bulliard, Sabhyata Sedhain, Odai Darawshi, Cigdem Elif Celik, Feyza Cansiz, Constantin P. Krempe, Jonas Rösler, Gabriele Allies, Sven W. Meckelmann, Chiashin Chi, Felix-Levin Hormann, Sven Heiles, Joseph Sedlak, Wesley Grace, George Eng, Ethan Reich, Chiara Alquati, Kevin J. Williams, Benjamin J. Read, Edrees H. Rashan, Zhixin Li, Anup Jnawali, Jose A. Ortiz, Chesta Jain, Charles A. Whittaker, Osman H. Yilmaz, Vikram Deshpande, Oliver J. Schmitz, Albert Sickmann, Autumn G. York, Douglas S. Kwon, Ulf Neumann, Maria Fedorova, Matthew G. Vander Heiden, Besim Ogretmen, Nilay S. Sethi, Alpaslan Tasdogan, Ömer H. Yilmaz

小鼠和患者来源类器官模型显示，神经酰胺合成通过PP2A–YAP驱动再生样细胞状态，增强CRC肝转移能力。

 16

Targeted therapy in advanced BRAF-mutated colorectal cancer: systematic review and network meta-analysis

Bao-Dong Qin, Xiao-Dong Jiao, Zhan Wang, Ke Liu, Yan Ling, Ying Wu, Yuan-Sheng Zang

系统综述与网络荟萃分析比较BRAF突变晚期CRC的靶向组合，并区分一线与后线证据。

 17

Prior therapy defines mutation profiles in childhood cancer at relapse

Mehdi Layeghifard, Marcos Díaz-Gay, Erik N. Bergstrom, Mathepan J. Mahendralingam, Nicholas Light, Sasha Blay, Joshua O. Nash, Nathaniel D. Anderson, Jessica N. Au, Scott Davidson, Pedro L. Ballester, Timmy Wen, Syed Kashif Daud, Lisa-Monique Edward, S. M. Ashiqul Islam, Azhar Khandekar, Burçak Otlu, Ledia Brunga, Rawan Hammad, Shimaa Nassif, Nirav H. Thacker, Tara Feltham, Noemi A. Fuentes-Bolanos, Marie Wong-Erasmus, Max F. Levine, Katherine E. Miller, Neerav N. Shukla, Michael D. Kinnaman, Dominik Glodzik, Carol Portwine, Sabrina Millson, Alexandra P. Zorzi, Mariam Mikhail, Conrad V. Fernandez, Laura Wheaton, Gunes Gundem, Andrew L. Kung, Uri Tabori, Chelsea Mayoh, Elli Papaemmanuil, Mark J. Cowley, David Malkin, Anita Villani, Ludmil B. Alexandrov, Adam Shlien

611份儿童肿瘤样本显示，铂类相关突变特征的检出与取样时间、突变数量及后续治疗反应有关。

 18

CD4+ T cells impair tumor growth via IL-3 and TNF-dependent vascular damage

Qiaoshi Lian, Jia Nie, Jatinder Singh, Qiang Chen, Jennifer Matta, Waipan Chan, Mariah Balmaceno-Criss, Melanie S. Vacchio, Weiming Yu, Alexander D. Clark, Elijah Edmondson, Michael C. Kelly, Ronald N. Germain, Rémy Bosselut

小鼠研究中，CD4 T细胞通过IL-3激活髓系细胞，以TNF依赖的血管损伤抑制肿瘤。

 19

Molecular glue degraders of HuR suppress BRAF-mutant colorectal cancer

Xiaocui Lu, Xiuyun Wang, Zheng Yang, Xusheng Wang, Lin Wang, Chunhui Xu, I-Chung Lo, Chenlu Geng, Lin Wang, Yisheng Pu, Keyu Zhang, Ziqiang Zhu, Lanxin Ye, Jiayuan Huang, Xiaofan Wei, Fang Bai, Yanan Zhu, Xiaobing Qian, Hao Dou, Hexiu Su, Yong Cang

HuR分子胶降解剂在BRAF突变结直肠癌模型中诱导外显子18跳读，并增强MAPK通路联合抑制。

 20

First-Line Retlirafusp Alfa Plus Chemotherapy for Human Epidermal Growth Factor Receptor 2–Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Randomized, Double-Blind, Phase III Study (RELIGHT)

Zhi Peng, Jufeng Wang, Yanqiao Zhang, Hongli Li, Qun Zhao, Xiaodong Zhu, Shaozhong Wei, Yan Chen, Wenhui Yang, Jun Yao, Mingjun Zhang, Lin Xie, Xizhi Zhang, Ping Zhao, Changlu Hu, Jingdong Zhang, Kangsheng Gu, Jun Bai, Yigui Chen, Zhongtao Zhang, Jun Zhang, Junsheng Wang, Zuoxing Niu, Yueyin Pan, Zhenyang Liu, Yanhong Deng, Zhigao Wang, Wenliang Wang, Hongxia Han, Lin Shen

RELIGHTⅢ期试验显示，retlirafusp alfa联合CAPOX延长总体及PD-L1 CPS≥5人群生存，CPS<1亚组出现不利信号。